In addition to COVID-19, bemnifosbuvir is also being developed in a Phase 2 clinical trial in combination with ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). As single agents, both bemnifosbuvir and ruzasvir have demonstrated potent pan-genotypic antiviral activity against HCV.
Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.
Hepatitis C (HCV)
HCV continues to be a healthcare crisis with number of new cases exceeding cures— global market in 2023 was approximately >$3 billion in net sales
Hepatitis C (HCV)
Executing global Phase 2 combination trial for bemnifosbuvir + ruzasvir in HCV patients
Leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology, we are discovering and developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Currently, we are focused on the development of orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV).
Updates on bemnifosbuvir, other Atea product candidates and company news.
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has engaged Evercore, a
Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration Regimen Was Generally Safe and Well-Tolerated Global Phase 3 Program Initiation Expected Early in 2025 BOSTON, Dec.
BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief
Atea is a clinical-stage biopharmaceutical company committed to addressing unmet medical needs through novel antiviral treatments.
Copyright © 2023 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use